Cismaru, Anca LilianaRudin, DeborahIbañez, LuisaLiakoni, EvangeliaBonadies, NicolasKreutz, ReinholdCarvajal, AlfonsoLucena, Maria IsabelMartin, JavierSancho Ponce, EstherMolokhia, MariamEriksson, NiclasEuDAC Collaborators,Krähenbühl, StephanLargiadèr, Carlo RHaschke, ManuelHallberg, PärWadelius, MiaAmstutz, Ursula2024-02-122024-02-122020-10-29http://hdl.handle.net/10668/16529http://hdl.handle.net/20.500.12105/18140Agranulocytosis is a rare yet severe idiosyncratic adverse drug reaction to metamizole, an analgesic widely used in countries such as Switzerland and Germany. Notably, an underlying mechanism has not yet been fully elucidated and no predictive factors are known to identify at-risk patients. With the aim to identify genetic susceptibility variants to metamizole-induced agranulocytosis (MIA) and neutropenia (MIN), we conducted a retrospective multi-center collaboration including cases and controls from three European populations. Association analyses were performed using genome-wide genotyping data from a Swiss cohort (45 cases, 191 controls) followed by replication in two independent European cohorts (41 cases, 273 controls) and a joint discovery meta-analysis. No genome-wide significant associations (pengVoRhttp://creativecommons.org/licenses/by/4.0/DipyroneDrug-induced agranulocytosisGenome-wide association studyMetamizolePharmacogeneticsAdultAgedAttribution 4.0 International33138277111110.3390/genes111112752073-4425Genesopen access